Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men with Castration Resistant Nonmetastatic Prostate Cancer

Researchers at the Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts performed an evaluation of the natural history of castration-resistant non-metastatic prostate cancer. For their analysis, the researchers used data from 331 subjects in a placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time [...]

Reported Antitumor Activity of MDV3100 in a Phase 1-2 Study of Advanced Prostate Cancer – A Great Success

At the on-going AUA Meeting, Dr. Howard Scher along with a collaborating group of medical oncologists reported their data from a Phase I-II trial of MDV3100 in castration-resistant prostate cancer (CRPC). […]

Timing IADT, Can “On Cycle” Time Periods Predict Outcomes?

A study by Yu et al., of men with a rising PSA after failed radical prostatectomy or radiation therapy who were placed on intermittent androgen deprivation therapy (IADT) indicated that the length of their first “off cycle” correlates with their expected time to developing castrate resistant prostate cancer (CRPC) and to their prostate cancer-specific mortality. [...]

C – Reactive Protein an Adverse Prognostic Marker for Men with Castration-Resistant Prostate Cancer

Many doctors believe that increased levels of C-reactive protein (CRP) is associated with adverse outcomes in men with castration-resistant prostate cancer (CRPC) treated with docetaxel. C-reactive protein is a protein found in the blood, the levels of which rise in response to inflammation in any part of the body. Traditionally measuring levels of c-reactive protein [...]

Positive Results from a Phase I-II Trial of MDV3100, Perhaps a New Alternative Hormone Blockade Option

There has been some positive news coming out of the ASCO conference in Florida this past week. One of the most significant pieces of positive news deals with the results of a phase I-II trial of the drug known as MDV3100. Basically, more than half of subjects in the study with castration-resistant prostate cancer responded [...]